BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9331009)

  • 21. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R; Porcellati C; Dusing R
    Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
    Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
    Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R; Wada T; Sanada T; Ojima M; Inada Y
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM; Keating GM
    Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide.
    Plouin PF
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S65-6. PubMed ID: 9331012
    [No Abstract]   [Full Text] [Related]  

  • 30. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
    Rapezzi C
    Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
    [No Abstract]   [Full Text] [Related]  

  • 31. Candesartan in the treatment of hypertension: what have we learnt in the last decade?
    Barrios V; Escobar C
    Expert Opin Drug Saf; 2011 Nov; 10(6):957-68. PubMed ID: 21848481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 33. [ACE inhibitors or AT1 receptor antagonists?].
    Riegger GA
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
    Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
    J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Candesartan cilexetil induced pustular psoriasis.
    Kawamura A; Ochiai T
    Eur J Dermatol; 2003; 13(4):406-7. PubMed ID: 12948927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
    Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
    Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
    Matsuo T; Ishikawa E; Ohta M; Shibouta Y; Ishimura Y; Imura Y; Sugiyama Y
    Jpn J Pharmacol; 2002 Mar; 88(3):300-6. PubMed ID: 11949885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.